AbbVie and Genmab Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL) AbbVie (NYSE: ABBV) and Genmab (Nasdaq: GMAB)…
FDA approves Pfizer’s LITFULO™ (ritlecitinib) for adults and adolescents with severe alopecia areata Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) has approved LITFULO™ (ritlecitinib),…
Magdeburg researchers discover a new mechanism of cancer immune defense Modern immunotherapies boost the body’s own defenses against cancer. They activate killer T cells of the immune system that can…
Kite Announces Completion of Marketing Authorization Transfer for Yescarta® CAR T-cell Therapy in Japan SANTA MONICA, Calif.–(BUSINESS WIRE)– Kite Pharma, Inc., a Gilead Company (Nasdaq: GILD), today announced that the Marketing…
Ad hoc announcement pursuant to Art. 53 LRFerring Pharmaceuticals appoints new Executive Chairman among key changes to Board of Directors Ferring Pharmaceuticals announced today that Jean-Frédéric Paulsen has been appointed…
WHO and Global Citizen sign a partnership to promote health, fight inequity and address health-related risks of climate change WHO and international advocacy organization Global Citizen today signed a memorandum…
The first year of the Long COVID project: What has been achieved? Since the 1st of June 2022, the Long COVID Consortium, led by HUS Helsinki University Hospital, is working…
Pfizer’s TALZENNA® in combination with XTANDI® receives U.S. FDA approval Pfizer (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) has approved TALZENNA (talazoparib), an oral poly ADP-ribose…
New anti-coagulants may help treat sepsis and COVID-19 Scientists from Trinity College Dublin have just discovered that the drug dimethylfumarate can block blood clotting during infection, offering hope that it…
For resistant breast cancers, two drugs may be better than one Cancer cells are even smarter than scientists previously believed, according to new CU Boulder research. When these cells are…
First-Of-Its-Kind Head-to-Head Clinical Trial Reaffirms the Efficacy of Emgality in Episodic Migraine Prevention Eli Lilly and Company (NYSE: LLY) announced results of the CHALLENGE-MIG clinical trial of Emgality® (galcanezumab-gnlm) and Nurtec® ODT (rimegepant…
Rabat Declaration adopted to improve refugee and migrant health Ministers and government representatives adopted a groundbreaking political declaration, the Rabat Declaration, to strengthen the global commitment to improve the health of…